(CN) - The Federal Trade Commission said it has fined Bristol-Myers Squibb $2.1 million for cutting a secret deal under which rival company Apotex agreed not to launch a generic version of Plavix, a blood thinner.
Bristol-Myers agreed to pay the fine for violating a 2003 FTC order requiring disclosure of such agreements, the FTC said.
Bristol-Myers failed to disclose the side deal, which it reached in a patent settlement, according to the FTC complaint. It says Apotex agreed to delay release of the generic drug for "several years," and that Bristol-Myers agreed not to compete with Apotex for 180 days after it did release the generic version.
Read the Top 8
Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.